AMED(AMED)
AMED
Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.
Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.
| Metric | FY2026E | FY2027E |
|---|---|---|
| Revenue Avg | $2.58B | $2.72B |
| Low | $2.53B | $2.71B |
| High | $2.65B | $2.73B |
| EBITDA Avg | $252M | $265M |
| Low | $247M | $264M |
| High | $259M | $266M |
| EBIT Avg | $222M | $234M |
| Low | $218M | $233M |
| High | $228M | $235M |
| Net Income Avg | $180M | $169M |
| Low | $156M | $163M |
| High | $184M | $199M |
| EPS Avg | $5.17 | $5.47 |
| Low | $4.73 | $4.93 |
| High | $5.57 | $6.01 |
| Analysts (Rev / EPS) | 8 / 6 | 1 / 2 |
| Metric | Q2 2026 | Q3 2026 | Q4 2026 | Q1 2027 | Q2 2027 | Q3 2027 | Q4 2027 |
|---|---|---|---|---|---|---|---|
| Revenue Avg | $645M | $644M | $656M | $660M | $683M | $683M | $691M |
| Low | $645M | $644M | $656M | $660M | $683M | $683M | $691M |
| High | $645M | $644M | $656M | $660M | $683M | $683M | $691M |
| EBITDA Avg | $63M | $63M | $64M | $64M | $67M | $67M | $67M |
| Low | $63M | $63M | $64M | $64M | $67M | $67M | $67M |
| High | $63M | $63M | $64M | $64M | $67M | $67M | $67M |
| EBIT Avg | $56M | $55M | $56M | $57M | $59M | $59M | $59M |
| Low | $56M | $55M | $56M | $57M | $59M | $59M | $59M |
| High | $56M | $55M | $56M | $57M | $59M | $59M | $59M |
| Net Income Avg | $48M | $41M | $40M | $45M | $47M | $46M | $43M |
| Low | $48M | $41M | $40M | $45M | $47M | $46M | $43M |
| High | $48M | $41M | $40M | $45M | $47M | $46M | $43M |
| EPS Avg | $1.45 | $1.23 | $1.23 | $1.37 | $1.42 | $1.40 | $1.30 |
| Low | $1.45 | $1.23 | $1.23 | $1.37 | $1.42 | $1.40 | $1.30 |
| High | $1.45 | $1.23 | $1.23 | $1.37 | $1.42 | $1.40 | $1.30 |
| Analysts (Rev / EPS) | 2 / 1 | 2 / 1 | 2 / 1 | 2 / 1 | 2 / 1 | 2 / 1 | 2 / 1 |